Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Long-term Debt
Borrowings due after more than one year.
Evommune, Inc.NYSE: EVMN
Long-term Debt · Q1 FY2026 · quarter ended Mar 2026
Long-term debt remains negative
Q1 FY2026 long-term debt was $0, compared with $191.78M a year earlier.
Context
- Long-term debt amounted to 0.0% of total assets at the end of Q1 FY2026, down 342.4 pp from a year earlier.
- Long-term debt increased in 1 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
What to watch
Whether long-term debt keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 191.78M | +28.4% |
| FY2023 | 2023-12-31 | 149.37M | — |
Long-term Debt vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 long-term debt of $0 is the 8th highest of the 10 companies compared; the peer median is $40.48M.
- Its year-over-year change of -100.0% is the lowest of 4, against a peer median of +24.1%.
- Long-term debt amounts to 0.0% of total assets for EVMN, versus a peer median of 31.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.13B | — | — | 51.5% | |
FTREFortrea Holdings Inc. | Jun 2026 | $1.04B | -5.8% | — | 38.2% |
| Sep 2026 | $597.15M | — | — | 50.8% | |
| Mar 2026 | $192.16M | +24.1% | +6.6% | 146.2% | |
| Mar 2026 | $40.48M | +38.7% | — | 31.3% | |
| Mar 2026 | $15.73M | — | — | 5.4% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $7.23M | — | — | 6.8% |
EVMNEvommune, Inc. | Mar 2026 | $0 | -100.0% | — | 0.0% |
CLYMClimb Bio, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding EVMN) | $40.48M | +24.1% | +6.6% | 31.3% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.